AnaSpec, EGT Group, provider of the long wavelength, ultra-sensitive
SensoLyte® assay kits, is pleased to offer custom service for the
development of assays. Our long wavelength SensoLyte® protease assays,
many of which utilize the 5-FAM/QXL™ 520 and HiLyte Fluor™ 488/QXL™ 520 FRET
pairs, have revolutionized the industry, setting the gold standard in fluorimetric
assay sensitivity (Figure 1). Our expertise in peptide chemistry, combined with
extensive experience in the syntheses of fluorescent dyes and quenchers, have
resulted in the development of ultra-sensitive, convenient, time-saving, cost-effective
assays. Researchers from the diagnostic, biotechnology, pharmaceutical and academic
sectors have reported the use of our assays in numerous publications in high
impact journals.
Committed to the highest levels of performance, our custom assay
development team will work with you to develop assays that will meet or exceed
your specific manufacturing and research priorities. Complete confidentiality
of all orders is assured.
• Design of optimized peptide substrates
• FRET, fluorimetric or luminometric technology
• Novel long wavelength FRET pairs, such as HiLyte Fluor™ 488/QXL™ 520
& 5-FAM/QXL™ 520
• Homogeneous assay
• Ideal for HTS (96 or 384-well format)
• Assay validation with purified enzyme and/or known inhibitor
• Validation with known inhibitor
• Assay parameters information included (sensitivity, linear range)
• Detailed protocol provided
Figure 1. The 5-FAM/QXL™ 520 renin FRET substrate is
40X more sensitive than the traditional EDANS/DABCYL FRET substrate and 10X
more sensitive than an Amp/Dnp FRET substrate. It can detect 0.8 ng/ml of renin.
Custom Inhibitor Screening Service
In addition to custom assay development service, AnaSpec also provides
custom inhibitor screening service for proteases such as HCV/HIV proteases;
renin; MMPs; cathepsin B, D, G, K, S and others.
Click
here to request a quotation.
Select literature citations:
SensoLyte®520
Renin Assay Kits
Sbroggio, M. et al. Cardiovasc Res. doi: 10.1093/cvr/cvr103 (2011).
Feliers, D. et al. Mol. Cell. Endocrinol. 314, 136(2010).
Iwai, M. et al. J. Hypertens. 28, 147(2010).
Du, D. et al. Mol. Biotech. 43, 1559 (2009).
Schmiedt, C. et al. Am. J. Vet. Res. 70, 1315 (2009).
Živná, M. et al. Am. J. Hum. Genet. 85, 204 (2009).
SensoLyte®
520 MMP Assay Kits
Mak, I. et al. Biochem. Res. Int. doi:10.1155/2011/164197
(2011).
Leong, D. et al. FASEB J. 25, 182 (2011).
Williams, J. et al. AJP Renal Physiol. doi: 10.1152/ajprenal.00262.2010 (2011).
Slanina, H. et al. J. Microbiol. Met. 84, 101 (2010).
Spiga, MG. And T. Borras Invest. Ophthal. Vis. Sc. doi:10.1167/iovs.09-4918 (2010).
Corriveau, MP. et al. J. Pathol. 217, 534 (2009).
Gueders, MM. et al. Biochem. Pharma. 75, 514 (2008).
Adiseshaiah, P. et al. J. Cell. Physiol. 216, 405 (2008).
Johnson, SL. et al. Bioorganic Chem. 35, 306 (2007).
Yi, F. et al. Kidney Int. 70, 88 (2006).
SensoLyte®
520 TACE Assay Kits
Zhao, XQ. et al. J. Lipid Res. doi: 10.1194/jlr.M015156 (2011).
Hassemer, EL. et al. Genetics doi:10.1534/genetics.109.113167 (2010).
Hurst, LA. et al. J Neuroimmunol 210, 108 (2009).
Walker, EJ. and GA. Rosenberg Exp Neuro 216, 122(2009).
Cardellini, M. et al. Diabetes 58, 2396 (2009).
|
